Covid-19 and its Ripple Effect on Clinical Trials
Our team came together to write an article on Covid-19 and its ripple effect on clinical trials for the Journal for Clinical Studies. Sofie Vandevyver, Daniel Tanner and Mario Papillon discussed the challenges Covid-19 revealed in clinical trials, the overwhelming amount of different assays for the detection of Covid-19 and which ones to use in clinical studies, and what the future of clinical trials might look like.
Download the article using the button below, or read a copy on the Journal for Clinical Studies’ website (https://issuu.com/mark123/docs/2020-jcs-3-june-web_compressed/22).
Challenges of Covid-19 Testing: Which Test to Use?
Are you using the right Covid-19 test? In the race to contain the COVID-19 pandemic, efficient detection of SARS-CoV-2 was and still remains the cornerstone. On January 23, the first in-house RT-PCR assay was published, quickly followed by the development of multiple commercial kits.
During the webinar, our Cerba biologists will walk participants through the overview of our available testing, discuss the reliability of tests, the current limits in Covid-19 testing, and which sample is the most efficient in each case.
Lastly, Cerba Research’s partner Fulgent will discuss NGS testing and how much we know about the analysis of the virus and its mutations.